US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.3218 -0.0147 (-4.37%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Chief Medical Officer Transition
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer 
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Friday's session ↗
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Thursday. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences in November
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy 
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
From Context Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >